APOA1, apolipoprotein A1, 335

N. diseases: 416; N. variants: 32
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 GeneticVariation group BEFREE Seven factors were associated with ICAS, as suggested by the meta-analysis, including advanced age (odds ratio (OR) 1.05, 95% CI 1.03-1.08), metabolic syndrome (OR 2.13, 95% CI 1.35-3.37), diabetes mellitus (OR 1.98, 95% CI 1.69-2.31), hypertension (OR 1.97, 95% CI 1.69-2.31), dyslipidemia (OR 1.29, 95% CI 1.04-1.59), high levels of low-density lipoprotein cholesterol (OR 1.06, 95% CI 1.00-1.12) and high levels of apolipoprotein A1 (OR 0.34, 95% CI 0.15-0.75). 30658194 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE Those with remission of hypertension had a significant weight loss (p < 0.001), decrease in body mass index (p < 0.001), 24-h total systolic BP (p = 0.047), baPWV (p = 0.042), triglycerides (p = 0.049) and apolipoprotein B/apolipoprotein A1 (p = 0.004), and an increase in high-density lipoprotein cholesterol (p < 0.001) at 1 year. 30317431 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE Eight correlations between clinical and epidemiological data and protein expression were noteworthy: diabetes mellitus vs. Ig gamma-2 and apolipoprotein-A1 and albumin; congestive heart failure vs. Ig lambda-2; colonization vs. actin; compressive therapy vs. Ig kappa; systemic arterial hypertension vs. alpha-2-macroglobulin and apolipoprotein-A1; area of ulcer vs. apolipoprotein-A1; race vs. heavy chain Ig and Ig γ-1 chain; age and race vs. Ig γ-1 chain. 30261322 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein (apo) B, apolipoprotein A-I (apoA-I), LDL particle and HDL particle concentrations were all decreased in PA subjects vs control subjects and subjects with untreated hypertension (P < 0.016). 30372543 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE Baseline urinary Hcy-thiolactone/creatinine was significantly associated with plasma tHcy, ApoA1, glomerular filtration rate, potassium and pyridoxal 5'-phosphate (positively) and with age, hypertension, smoking, urinary creatinine, plasma bilirubin and kynurenine (negatively). 30193001 2019
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 Biomarker disease GENOMICS_ENGLAND A novel APOA1 mutation in a patient with renal amyloidosis: unveiling amyloid by next-generation sequencing. 31482740 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE HDL-C (for PVWMLs: OR 0.36, 95% CI 0.19-0.71; for DWMLs: OR 0.35, 95% CI 0.20-0.63) and apoA-1 (for PVWMLs: OR 0.27, 95% CI 0.11-0.66; for DWMLs: OR 0.22, 95% CI 0.10-0.48) were inversely associated with the severity of PVWMLs and DWMLs in women but not in men after adjustment for age, hypertension, diabetes, current smoking, daily drinking, body mass index and uric acid. 29162363 2018
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 Biomarker disease GENOMICS_ENGLAND A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype. 27240838 2016
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 Biomarker disease GENOMICS_ENGLAND Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308 2016
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 GeneticVariation group BEFREE This study investigated the relationship between the MTHFR polymorphism and hypertension and correlated blood lipid indexes, including homocysteine (HCY), lipoprotein (a) [Lp (a)], high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein A I (Apo AI), Apo B, glucose (GLU), total cholesterol (TC), and triglyceride (TG), in a Chinese population. 25489783 2015
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. 24963038 2014
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group BEFREE The HTN-induced increase in leukocyte and platelet adhesion was attenuated in apolipoprotein A-I transgenic mice (ApoA1-Tg) and blunted in wild-type mice treated with the ApoA1 mimetic peptide, 4F. 23281427 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group RGD High blood pressure effects on the blood to cerebrospinal fluid barrier and cerebrospinal fluid protein composition: a two-dimensional electrophoresis study in spontaneously hypertensive rats. 23401751 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 GeneticVariation group BEFREE APOA1 polymorphisms analysis may be a useful tool to identify risk factors for subjects and families and clarify the physiopathological role of these polymorphisms in age-related diseases, such as hypertension and obesity. 19408098 2009
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group CTD_human Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I. 18224302 2008
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 Biomarker disease GENOMICS_ENGLAND Organ transplantation in hereditary apolipoprotein AI amyloidosis. 16925563 2006
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 AlteredExpression group BEFREE The presence of CAD was associated with current, past or passive smoking, a history of diabetes and high blood pressure, a positive family risk factors in this study; levels were below history of CAD, body fat percentage, waist-hip ratio (WHR), low apolipoprotein A1 or low HDL, lipoprotein (a), glucose, insulin, insulin resistance, C-reactive protein (CRP), total cholesterol to HDL ratio (TC/HDL) and creatinine on univariate conditional logistic regression analysis. 14741073 2004
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 GeneticVariation group LHGDN Apolipoprotein AI promoter variant in blood pressure determination. 12030900 2002
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 GeneticVariation disease UNIPROT Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. 8208902 1994
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 GeneticVariation disease UNIPROT Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. 1502149 1992
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 GeneticVariation disease UNIPROT A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. 2123470 1990
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 GeneticVariation disease UNIPROT Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. 3142462 1988
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.700 Biomarker group HPO
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 CausalMutation disease CLINVAR
CUI: C0268389
Disease: Amyloidosis, familial visceral
Amyloidosis, familial visceral
0.700 Biomarker disease CTD_human